AbCellera Biologics Inc.
11.82USD
+0.4500 (+3.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ABCL.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.18▼ | -$0.18 | 1 | 0 |
| Next quarter | -$0.17▲ | -$0.18 | 2 | 1 |
| Current year | -$0.67▼ | -$0.63 | 1 | 3 |
| Next year | -$0.76▼ | -$0.71 | 2 | 1 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.17 | -$0.18 | -0.01 (-9.1%) |
| 2026-03-31 | -$0.2 | -$0.14 | +0.06 (+29.1%) |
| 2025-12-31 | -$0.18 | -$0.03 | +0.15 (+83.3%) |
| 2025-09-30 | -$0.16 | -$0.19 | -0.03 (-17.3%) |
52 ratings from 16 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Initiated | Buy | $18 | Oct 12, 2026 |
| JP Morgan | Initiated | Overweight | $17 | Sep 29, 2026 |
| Truist Securities | Maintained | Buy | $12 $30 | Aug 11, 2026 |
| Stifel | Maintained | Buy | $8 $9 | Aug 6, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $11 $12 | Aug 6, 2026 |
| Benchmark | Upgraded from Hold | Buy | $11 | Jul 7, 2026 |
| Cantor Fitzgerald | Initiated | Overweight | $7 | May 5, 2026 |
| Jones Trading | Initiated | Buy | $11 | Apr 10, 2026 |
| Leerink Partners | Downgraded from Outperform | Market Perform | $4 | Nov 7, 2025 |
| Stifel | Maintained | Buy | $8 $7 | Aug 8, 2025 |
| Keybanc | Maintained | Overweight | $5 $10 | Jul 14, 2025 |
| Truist Securities | Maintained | Buy | $28 $10 | May 16, 2025 |
| Stifel | Maintained | Buy | $10 $8 | May 9, 2025 |
| Keybanc | Maintained | Overweight | $4 $5 | Apr 16, 2025 |
| Benchmark | Reiterated | Hold | — | Mar 3, 2025 |
| Stifel | Maintained | Buy | $12 $10 | Feb 28, 2025 |
| Keybanc | Maintained | Overweight | $5 $4 | Jan 8, 2025 |
| Benchmark | Reiterated | Hold | — | Nov 5, 2024 |
| Stifel | Reiterated | Buy | $14 $12 | Nov 5, 2024 |
| Benchmark | Downgraded from Buy | Hold | — | Aug 20, 2024 |
| Keybanc | Maintained | Overweight | $7 $5 | Jul 11, 2024 |
| Keybanc | Maintained | Overweight | $8 $7 | May 8, 2024 |
| Benchmark | Upgraded from Hold | Buy | — | Feb 22, 2024 |
| Stifel | Maintained | Buy | $21 $17 | Feb 21, 2024 |
| Keybanc | Initiated | Overweight | $6 | Dec 5, 2023 |
19 filings from 5 insiders · 0 buy / 0 sell over 6m
Officers and directors of ABCL, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HAYDEN MICHAEL REUBENDirector | Buyindirect | 53.6k | $10.64 | $570k | Aug 24, 2026 |
| MONTALBANO JOHN S.Director | Buy | 10.0k | $11.03 | $110k | Aug 18, 2026 |
| BOOTH ANDREWChief Financial Officer | Buy | 37.2k | $10.32 | $384k | Aug 14, 2026 |
| HAYDEN MICHAEL REUBENDirector | Buyindirect | 46.4k | $10.37 | $481k | Aug 12, 2026 |
| HAYDEN MICHAEL REUBENDirector | Giftindirect | 50.0k | — | — | Aug 11, 2026 |
| BOOTH ANDREWChief Financial Officer | Exercise | 250.0k | $0.19 | $48k | Jun 3, 2026 |
| MONTALBANO JOHN S.Director | Buy | 20.0k | $4.77 | $95k | May 14, 2026 |
| THERMOPYLAE HOLDINGS, LTD.Beneficial Owner of more than 10% of a Class of Security | Buy | 38.0k | $3.44 | $131k | Feb 27, 2026 |
| BOOTH ANDREWChief Financial Officer | Buy | 42.6k | $3.42 | $146k | Feb 27, 2026 |
| THERMOPYLAE HOLDINGS, LTD.Beneficial Owner of more than 10% of a Class of Security | Buy | 177.5k | $3.27 | $580k | Feb 26, 2026 |
| THERMOPYLAE HOLDINGS, LTD.Beneficial Owner of more than 10% of a Class of Security | Gift | 225.0k | — | — | Dec 18, 2025 |
| MONTALBANO JOHN S.Director | Buy | 50.0k | $3.57 | $178k | Nov 26, 2025 |
| THERMOPYLAE HOLDINGS, LTD.Beneficial Owner of more than 10% of a Class of Security | Buy | 343.6k | $2.16 | $742k | Mar 11, 2025 |
| MONTALBANO JOHN S.Director | Buy | 25.0k | $2.30 | $58k | Mar 10, 2025 |
| MONTALBANO JOHN S.Director | Buy | 60.0k | $2.34 | $141k | Mar 6, 2025 |
| THERMOPYLAE HOLDINGS, LTD.Beneficial Owner of more than 10% of a Class of Security | Gift | 286.0k | — | — | Dec 4, 2024 |
| HANSEN CARL L.G.Chief Executive Officer | Exercise | 56.1k | $2.70 | $152k | Nov 25, 2024 |
| HANSEN CARL L.G.Chief Executive Officer | Exercise | 56.1k | $2.70 | $152k | Sep 20, 2024 |
| THERMOPYLAE HOLDINGS, LTD.Beneficial Owner of more than 10% of a Class of Security | Buy | 283.5k | $2.61 | $740k | Aug 29, 2024 |
No analyst notes on ABCL yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 9 | 1 | 0 | 0 | Buy1.92 |
| 1 mo ago | 2 | 8 | 1 | 0 | 0 | Buy1.91 |
| 2 mo ago | 1 | 8 | 0 | 0 | 0 | Buy1.89 |
| 3 mo ago | 1 | 8 | 0 | 0 | 0 | Buy1.89 |
Members whose judged calls on ABCL have played out most reliably.
No settled calls on ABCL yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice